Investment Rating - The report maintains an "Overweight" rating for the pharmaceutical and biotechnology industry [1]. Core Insights - The National People's Congress has designated innovative drugs as a "new emerging pillar industry," indicating a strategic shift for the biopharmaceutical sector from a nurturing phase to a key driver of economic growth [16][17]. - As of March 6, 2026, the total contract value for Chinese innovative drug outbound business development (BD) has reached USD 56.8 billion, with an upfront payment of USD 3.3 billion, representing 41% of the total for 2025 and exceeding the total for 2024 [17][21]. - Despite significant stock price corrections from 2025 highs, the fundamental outlook for quality companies remains strong, with ongoing clinical development and internationalization efforts [21]. Summary by Sections Industry Trends - The A-share pharmaceutical index has seen a year-to-date decline of 2.42%, underperforming the CSI 300 by 1.02% [9]. - The Hang Seng Healthcare Index has outperformed the Hang Seng Technology Index by 0.97% year-to-date [9]. R&D Progress and Company Dynamics - Recent approvals include HSK31679 for non-alcoholic fatty liver disease and the GLP-1 receptor agonist Enogratide, marking significant advancements in innovative drug development [17]. - The report highlights specific companies to watch, including: - PD1 PLUS: Sangamo Therapeutics, CanSino Biologics, Innovent Biologics, and Zai Lab [12]. - ADC: I-Mab Biopharma, Kelun-Biotech, and Baillie Gifford [12]. - Small nucleic acids: Frontier Biotechnologies, Fuyuan Pharmaceutical, and Yuyuan Pharmaceutical [12]. Market Performance - The report notes that the pharmaceutical index's price-to-earnings ratio is currently at 36.18, which is 2.24 times lower than the historical average [9]. - The report identifies high-performing stocks such as Yahu Pharmaceutical (+40.65%) and Duoyi Pharmaceutical (+30.81%) for the week, while stocks like Haixiang Pharmaceutical (-15.06%) and Furu Medical (-13.07%) faced significant declines [9].

Investment Rating - The report maintains an "Overweight" rating for the pharmaceutical and biotechnology industry [1]. Core Insights - The National People's Congress has designated innovative drugs as a "new emerging pillar industry," indicating a strategic shift for the biopharmaceutical sector from a nurturing phase to a core engine of economic growth [16][17]. - As of March 6, 2026, the total value of business development (BD) contracts for Chinese innovative drugs has reached $56.8 billion, with an upfront payment of $3.3 billion, representing 41% of the total for 2025 and exceeding the total for 2024 [17][21]. - Despite significant stock price corrections from 2025 highs, the fundamentals of quality companies remain solid, and the long-term growth logic for innovative drug exports is still intact [21]. Summary by Sections Industry Trends - The A-share pharmaceutical index has seen a year-to-date decline of 2.42%, underperforming the CSI 300 by 1.02% [9]. - The Hang Seng Healthcare Index has outperformed the Hang Seng Technology Index by 0.97% year-to-date [9]. R&D Progress and Company Dynamics - Recent approvals include HSK31679 for non-alcoholic fatty liver disease and the GLP-1 receptor agonist Enogratide, marking significant advancements in innovative drug development [17]. - The report highlights specific companies to watch, including: - PD1 PLUS: Sangamo Therapeutics, CanSino Biologics, Innovent Biologics, and Zai Lab [12]. - ADC: I-Mab Biopharma, Kelun-Biotech, and Baiyue Tianheng [12]. - Small nucleic acids: Frontier Biotechnologies, Fuyuan Pharmaceutical, and Yuyuan Pharmaceutical [12]. Market Performance - The report notes that the pharmaceutical index's price-to-earnings ratio is currently at 36.18, which is 2.24 times lower than the historical average [9]. - The report identifies top-performing stocks for the week, including Yahu Pharmaceutical (+40.65%) and Duoyi Pharmaceutical (+30.81%), while highlighting significant declines in stocks like Haixiang Pharmaceutical (-15.06%) and Furu Medical (-13.07%) [9].

证券代码：002675 证券简称：东诚药业 公告编号：2026-012 烟台东诚药业集团股份有限公司 关于 225Ac-LNC1011 注射液 I 期临床试验 完成首例参与者入组的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 近日，烟台东诚药业集团股份有限公司（以下简称"公司"）控股子公司烟 台蓝纳成生物技术股份有限公司（以下简称"蓝纳成"）自主研发的 225Ac-LNC1011 注射液 I/II 期临床完成了首例参与者入组。该研究为一项评价 225Ac-LNC1011 注 射液在前列腺特异性膜抗原（PSMA）阳性的转移性去势抵抗性前列腺癌（mCRPC） 患者中的安全性、耐受性、药代动力学及初步有效性的 I/II 期临床试验。 药品从研制、临床试验报批到投产的周期长、环节多，药品研发及至上市容 易受到一些不确定性因素的影响，敬请广大投资者谨慎决策，注意防范投资风险。 公司将按相关国家的有关规定积极推进上述研发项目，并及时对项目后续进展情 况履行信息披露义务。 特此公告。 烟台东诚药业集团股份有限公司董事会 二、药物的其他情况 1、225Ac-LNC10 ...

证券代码：002675 证券简称：东诚药业 公告编号：2026-011 烟台东诚药业集团股份有限公司 关于回购公司股份进展情况的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 烟台东诚药业集团股份有限公司（以下简称"公司"）于2025年12月31日召开 第六届董事会第十七次会议，审议通过了《关于以集中竞价方式回购股份方案的 议案》，同意公司使用自有资金及自筹资金以集中竞价交易的方式回购公司股份， 回购的股份将用于实施股权激励和/或员工持股计划。回购价格不超过人民币 18.00元/股（含），回购资金总额不低于人民币10,000万元（含），不超过人民 币20,000万元（含），回购期限自公司董事会审议通过回购股份方案之日起不超 过12个月。具体内容详见公司于2026年1月5日、2026年1月6日在巨潮资讯网 （www.cninfo.com.cn）披露的《关于以集中竞价方式回购股份方案的公告》、 《回购报告书》。 根据《深圳证券交易所上市公司自律监管指引第9号——回购股份》等相关 规定，回购期间公司应当在每个月的前三个交易日内披露截至上月末的回购进展 情况。现 ...

2月25日，东诚药业涨0.97%，成交额1.12亿元。两融数据显示，当日东诚药业获融资买入额1488.08万 元，融资偿还910.00万元，融资净买入578.08万元。截至2月25日，东诚药业融资融券余额合计10.75亿 元。 机构持仓方面，截止2025年12月31日，东诚药业十大流通股东中，香港中央结算有限公司位居第五大流 通股东，持股2027.93万股，相比上期增加25.21万股。 声明：市场有风险，投资需谨慎。本文基于第三方数据库自动发布，不代表新浪财经观点，任何在本文 出现的信息均只作为参考，不构成个人投资建议。如有出入请以实际公告为准。如有疑问，请联系 biz@staff.sina.com.cn。 责任编辑：小浪快报 资料显示，烟台东诚药业集团股份有限公司位于山东省烟台经济技术开发区长白山路7号，成立日期 1998年12月31日，上市日期2012年5月25日，公司主营业务涉及肝素钠原料药、硫酸软骨素的研发、生 产和销售。主营业务收入构成为：原料药相关产品44.16%，核药产品36.38%，制剂产品13.17%，其他 6.30%。 截至9月30日，东诚药业股东户数2.46万，较上期增加4.51%；人均 ...

证券代码：002675 证券简称：东诚药业 公告编号：2026-010 烟台东诚药业集团股份有限公司 关于为下属公司提供担保的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 一、本次担保情况概述 近日，烟台东诚药业集团股份有限公司（以下简称"公司"）与中国光大银 行股份有限公司烟台分行（以下简称"光大银行"或"债权人"）签订了《保证 合同》，约定公司为下属公司烟台东诚核源技术开发有限公司（以下简称"东诚 核源"或"债务人"）向光大银行申请的20,000万元贷款提供连带责任担保。 二、担保事项审议及额度使用情况 公司于2025年2月26日和2025年3月28日分别召开第六届董事会第九次会议 和2024年度股东大会，审议通过了《关于2025年度为子公司及其下属公司提供担 保额度预计的议案》，同意公司对合并报表范围内的子公司及其下属公司提供担 保，预计2025年度上述担保额度合计不超过人民币100,000万元（或等值外币）， 额度内可循环滚动操作。授权公司及子公司法定代表人或其授权人员根据实际经 营需要，在前述额度内分别代表其所在公司签署相关文件。 内容详 ...

证券日报网讯2月1日，东诚药业（002675）发布公告称，截至2026年1月31日，公司通过股份回购专用 证券账户以集中竞价方式回购公司股份4，028，699股，占公司总股本的比例为0.49%。 ...

Investment Rating - The report maintains an "Overweight" rating for the pharmaceutical and biotechnology industry, with a focus on companies like Haoyuan Pharmaceutical and Aopumai [1]. Core Insights - The report highlights a recovery in the upstream research sector supported by interest rate cuts and other factors, indicating a renewed focus on early-stage research projects by pharmaceutical companies [4][16]. - The A-share pharmaceutical index has shown a year-to-date increase of 3.14%, outperforming the CSI 300 index by 2.51% [4]. - The report emphasizes the importance of innovation in drug development, particularly in early-stage projects, and suggests that the demand for life sciences services will increase as funding becomes more available [4][16]. Summary by Sections Industry Trends - The A-share pharmaceutical index has decreased by 3.31% this week, while the Hang Seng Biotechnology Index has decreased by 3.24% [4][9]. - The report notes that the pharmaceutical sector is experiencing a rebound in demand, driven by both domestic and international factors, including a resurgence in IPOs and funding opportunities [16][18]. Research and Development Progress - The report details significant advancements in innovative drugs and improved drugs, with several companies submitting applications for new drug approvals [20]. - Companies like Roche and Relay Therapeutics are making strides in clinical trials, with Roche submitting an application for Giredestrant for breast cancer treatment [4][20]. Recommended Stocks - The report suggests focusing on specific companies based on sub-industry strengths, including: - CXO and upstream research services: WuXi AppTec, Haoyuan Pharmaceutical, Aopumai, and King’s Ray Biotechnology [12]. - Traditional Chinese medicine: Jichuan Pharmaceutical, Zuoli Pharmaceutical, and Fangsheng Pharmaceutical [12]. - PD1 PLUS: 3SBio, Kangfang Biotech, and Innovent Biologics [12]. - ADC: InnoCare Pharma and Kelun-Biotech [12]. - AI drug development: Jingtaikong Holdings [12].

每经AI快讯，东诚药业2月1日晚间发布公告称，截至2026年1月31日，公司通过股份回购专用证券账户 以集中竞价方式回购公司股份约403万股，占公司总股本的比例为0.49%，最高成交价为14.74元/股，最 低成交价为13.87元/股，支付的资金总额为人民币约5717万元。 （记者 王晓波） 每经头条（nbdtoutiao）——特朗普大动作，金价30小时暴跌670美元！此前两周狂飙21%，也与他有 关！后市怎么走？各大机构表态，专家解读 ...

东诚药业2月1日公告，截至2026年1月31日，公司通过股份回购专用证券账户以集中竞价方式回购公司 股份4,028,699股，占公司总股本的比例为0.49%，最高成交价为14.74元/股，最低成交价为13.87元/股， 支付的资金总额为人民币57,171,909.70元（不含交易费用）。本次回购符合相关法律法规及公司既定的 回购股份方案。 ...